Abstract: The present invention relates to a combination, in particular for the adhesive bonding and/or fixing of biological and/or synthetic tissues, wherein the combination comprises the components a) a nitrogen-functionalized polysaccharide and b) a terminally functionalized oligolactone.

Abstract: The present invention relates to a combination for the treatment of osteoporosis and/or the prophylaxis and treatment of bone fractures, said combination comprising collagen, an additional peptide, a calcium-containing substance and a wetting agent with a terminally functionalized oligolactone. The invention also relates to artificial bones and implants produced by the combination and to the use of said combination for fixing implants and treating osteoporosis and/or the prophylaxis and treatment of bone fractures. The invention further relates to a method for producing artificial bones and implants.

Abstract: An electrode arrangement for sensing electrical activity in target tissue is described. A support electrode has an elongate electrode body with a base end and a penetrating end for insertion into the target tissue. A fixation electrode has an elongate electrode body with a base end and a penetrating end at an angle to the electrode body. The electrodes are joined together with their electrode bodies in parallel so that the penetrating end of the fixation electrode penetrates a fixed distance into the target tissue so that at least one of the electrodes senses electrical activity in the target tissue.

Abstract: The present invention relates to an ocular implant, particularly a glaucoma stent. It is the object of the present invention to devise an ocular implant which allows the ocular eye pressure to be regulated, i.e., to be maintained at a desired level, while preventing the flow resistance from increasing over time, for example due to fibrosis. In order to achieve this object, the ocular implant according to the invention comprises a small tube (5), the wall surface (3) of which encloses a hollow duct that is open on both sides in the longitudinal direction of the hollow duct, wherein a first opening (1) allowing ocular humor to flow in and a second opening (2) allowing the ocular humor to be discharged is provided, and wherein the wall surface (3) is formed by a liquid-tight material, and wherein at least one pressure-controlled valve (4) is disposed in the area of the wall surface (3).

Abstract: Absorbable stents and absorbable stent coatings have been developed with improved properties. These devices preferably comprise biocompatible copolymers or homopolymers of 4-hydroxybutyrate, and optionally poly-L-lactic acid and other absorbable polymers and additives. Compositions of these materials can be used to make absorbable stents that provide advantageous radial strengths, resistance to recoil and creep, can be plastically expanded on a balloon catheter, and can be deployed rapidly in vivo. Stent coatings derived from these materials provide biocompatible, uniform coatings that are ductile, and can be expanded without the coating cracking and/or delaminating and can be used as a coating matrix for drug incorporation.

Abstract: An implant for implantation in a human or animal body having a structure comprising a) an implant base body; b) a primer layer which is partially or completely applied to the surface of the implant; c) an active ingredient layer consisting of one, two, three or more active ingredients applied entirely or partially to the surface of the primer layer; and d) a diffusion-controlling layer which is applied partially or entirely to the active ingredient layer, and optionally to the primer layer, wherein diffusion of the active ingredients of the active ingredient layer is controlled. Also disclosed is a manufacturing method for an implant.

Abstract: Absorbable stents and absorbable stent coatings have been developed with improved properties. These devices preferably comprise biocompatible copolymers or homopolymers of 4-hydroxybutyrate, and optionally polylactic acid and other absorbable polymers and additives. Compositions of these materials can be used to make absorbable stents that provide advantageous radial strengths, resistance to recoil and creep, can be plastically expanded on a balloon catheter, and can be deployed rapidly in vivo. Stent coatings derived from these materials provide biocompatible, uniform coatings that are ductile, and can be expanded without the coating cracking and/or delaminating and can be used as a coating matrix for drug incorporation.

Abstract: Absorbable stents and absorbable stent coatings have been developed with improved properties. These devices preferably comprise biocompatible copolymers or homopolymers of 4-hydroxybutyrate, and optionally poly-L-lactic acid and other absorbable polymers and additives. Compositions of these materials can be used to make absorbable stents that provide advantageous radial strengths, resistance to recoil and creep, can be plastically expanded on a balloon catheter, and can be deployed rapidly in vivo. Stent coatings derived from these materials provide biocompatible, uniform coatings that are ductile, and can be expanded without the coating cracking and/or delaminating and can be used as a coating matrix for drug incorporation.

Abstract: The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPAR?-agonists, PPAR?-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists.

Abstract: A stent made of a biocorrodible metallic material and having a coating or cavity filling which contains genistein.

Abstract: Absorbable stents and absorbable stent coatings have been developed with improved properties. These devices preferably comprise biocompatible copolymers or homopolymers of 4-hydroxybutyrate, and optionally poly-L-lactic acid and other absorbable polymers and additives. Compositions of these materials can be used to make absorbable stents that provide advantageous radial strengths, resistance to recoil and creep, can be plastically expanded on a balloon catheter, and can be deployed rapidly in vivo. Stent coatings derived from these materials provide biocompatible, uniform coatings that are ductile, and can be expanded without the coating cracking and/or delaminating and can be used as a coating matrix for drug incorporation.

Abstract: The invention concerns an endovascular implant, in particular a stent, with an at least portion-wise active coating. The object of the present invention is to provide locally therapeutic formulations for the treatment of stenosis or restenosis. The implants modified in accordance with the invention are to ensure improved compatibility, in particular in regard to any inflammatory and proliferative processes in the tissue environment. That is achieved in that the active coating includes, as an active substance: 1) PPAR&agr;-agonists, PPAR&dgr;-agonists or a combination thereof; 2) an RXR-agonist; or 3) a combination of PPAR-agonists and RXR-agonists.

Abstract: The invention concerns an implantable stent (10) with an at least portion-wise polymeric coating (16). The coating material is admittedly intended to bond to known materials but by virtue of its properties it is intended to enjoy improved compatibility and reduce inflammatory and proliferative processes which can lead to restenosis. That is achieved in that the polymeric coating (16) in the implantable condition after production and sterilization contains poly-L-lactide of a mean molecular weight of more than 200 kDa.